Fig. 3From: Randomised, double-blind, placebo-controlled crossover study to investigate different dosing regimens of olodaterol delivered via Respimat® in patients with moderate to severe persistent asthmaAdjusted mean FEV1: individual time points from 0 to 24 h at 3 weeks. Analysis with imputation, full analysis set. BID: twice daily; QD: once daily; FEV1: forced expiratory volume in 1 sBack to article page